Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5850 - The SLICE study: the prognostic role of viSceraL fat In metastatic Colorectal cancEr

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Translational Research

Tumour Site

Colon and Rectal Cancer

Presenters

Debora Basile

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

D. Basile1, C. Lisanti1, M. Borghi2, M. Bartoletti1, L. Gerratana1, L. Bortot1, G. Pelizzari1, C. Corvaja1, E. Ongaro3, S.K. Garattini1, V. Fanotto1, A. Parnofiello1, F. Cortiula1, M. Cattaneo3, V.J. Andreotti1, E. Bertoli1, M. Guardascione4, G. Miolo5, F. Puglisi6, A. Buonadonna5

Author affiliations

  • 1 Department Of Medicine (dame), University of Udine, 33100 - Udine/IT
  • 2 Intensive Care Unit, CRO National Cancer Institute, 33081 - Aviano/IT
  • 3 Department Of Medicine (dame), University of Udine, 33100 - udine/IT
  • 4 Clinical And Experimental Pharmacology, CRO National Cancer Institute, 33081 - Aviano/IT
  • 5 Department Of Medical Oncology And Cancer Prevention, CRO National Cancer Institute, 33081 - Aviano/IT
  • 6 University Of Udine - Udine, Italy; Department Of Medical Oncology And Cancer Prevention, CRO National Cancer Institute, 33081 - Aviano/IT
More

Resources

Abstract 5850

Background

Body composition, more specially the excess of body weight, was established as a risk factor of the colorectal cancer initiation and progression. Aim of this study was to investigate the prognostic role of adiposity, especially visceral fat (VAT), in metastatic colorectal cancer (MCRC).

Methods

This retrospective study analyzed a consecutive cohort of 71 patients (pts) with MCRC treated between 2013 and 2017 at the Oncology Department of Aviano National Cancer Institute (Italy). VAT area was measured as cross-sectional (cm2) area at the L3 level divided by the square of the height (m2). A ROC analysis was performed to define a threshold capable to identify distinct prognostic categories of patients according to VAT. Subsequently, the value of VAT in predicting overall survival (OS) and progression free survival (PFS) was evaluated with uni- and multivariate Cox regression analyses. Survival outcomes were estimated with Kaplan-Meier curves.

Results

Before first line therapy, 19 pts (27%) were aged>70, 14 pts (20%) had a right tumor, 21 pts (30%) a left tumor and 35 pts (50%) a rectal one. Of note, 59 pts (83%) underwent primitive tumor resection and 24 pts (33%) received metastasectomy. Interestingly, 40 pts (56%) had a body mass index (BMI)>25 and 42 (59%) had median VAT of 51.94. LDH level > =480 UI/L was recorded in 12 pts (27%) reflecting the inflammatory response. The obtained cut-off for VAT was 44. Median OS was 30.97 months. At univariate analysis, older age (HR 2.46, p = 0.013), primary tumor resection (HR 0.40, p = 0.029), VAT>44 (HR 2.85, p = 0.011), metastasectomy (HR 0.22, p = 0.005), were significantly associated with OS. By multivariate analysis, only VAT>44 (HR2.64; p = 0.030) was significantly associated with OS. Conversely, VAT showed no prognostic impact in terms of PFS.

Conclusions

This exploratory study supported the prognostic role of adiposity evaluation in patients with MCRC. In particular, high values of VAT were predictors of worse outcome. These encouraging preliminary data merit to be validated through prospective investigations.

Clinical trial identification

Legal entity responsible for the study

University of Udine.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.